Emerging therapeutic targets for NASH: key innovations at the preclinical level.
Horn, Paul Newsome, Phlip N
Horn, Paul
Newsome, Phlip N
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2020-02-13
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Introduction: nonalcoholic steatohepatitis (NASH) is a globally emerging health problem, mainly caused by increasing trends in the prevalence of obesity and metabolic syndrome. Patients with NASH are mainly affected by cardiovascular risk and extrahepatic cancer, but a significant proportion of patients will develop advanced liver disease, eventually resulting in liver failure or hepatocellular carcinoma. Recent research has yielded a better understanding of the underlying mechanisms and potential targetability for drug development.Areas covered: This review focuses on the role of fructose metabolism, de novo lipogenesis (DNL), endoplasmic reticulum (ER) stress, NLRP3 inflammasome, bone morphogenetic protein (BMP) signaling and platelets in the pathophysiology of NASH. We discuss the suitability of these substrates for targeting liver disease as well as cardiovascular health in patients with NASH. A non-systematic literature search was performed on PubMed and ClinicalTrials.gov.Expert opinion: Targeting fructose metabolism, DNL, ER stress, NLRP3 inflammasome, BMP signaling and platelets are promising therapeutic strategies, warranting further preclinical and clinical investigation. The discussed approaches might not only benefit liver-related outcomes but improve cardiovascular disease as well. Amidst the euphoria of advances in drug development for NASH, parallel endeavors need to address the underlying causes of obesity and metabolic syndrome to prevent NASH.
Citation
Horn P, Newsome PN. Emerging therapeutic targets for NASH: key innovations at the preclinical level. Expert Opin Ther Targets. 2020 Mar;24(3):175-186. doi: 10.1080/14728222.2020.1728742. Epub 2020 Feb 13
Type
Article
Other
Other